Open AccessEfficacy of 6-month therapy with Seretid of chronic obstructive lung disease
Author(s) -
B. A. Chernyak,
И. Н. Трофименко
Publication year - 2005
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2005-0-4-86-91
Subject(s) - medicine , tolerability , salbutamol , fluticasone propionate , salmeterol , copd , exacerbation , metered dose inhaler , quality of life (healthcare) , sputum , inhaler , randomized controlled trial , fluticasone , anesthesia , physical therapy , asthma , adverse effect , tuberculosis , nursing , pathology
The efficacy of salmeterol/fluticasone propionate (S / FP) (Seretid, GlaxoSmithKline) was studied in a randomized open comparative trial in parallel groups. The study involved 36 patients with severe COPD (GOLD, 2003). The 1st group patients (n = 18) received S / FP f 50 / 500 mcg daily using dose-metered aerosol inhaler 25 / 250 mcg and salbutamol (Ventolin, GlaxoSmithKline) if needed for 6 months. The 2nd group patients (n = 18) kept receiving short-acting beta-2-agonists alone (salbutamol, Berotec, Berodual, or Atrovent) in the mode as before the study. The efficacy of the treatment was evaluated with regards to severity of dyspnea and cough, sputum production, FEV1, physical tolerability (6-minute walk test — 6MWT), quality of life (QoL). The QoL was assessed using a Russian version of the St. George's Respiratory Questionnaire (SGRQ). The study showed a high efficacy of S / FP for treatment in severe COPD resulted in significant reduction in the COPD signs and symptoms, bronchial obstruction, exacerbation rate, improvement of the physical tolerability and the QoL when compared both to the baseline parameters and to the control group.